AI-generated summary
The authors studied whether photobiomodulation at 630 nm and 980 nm could reduce doxorubicin resistance in MDA-MB-231 breast cancer cells grown in the laboratory. They report that combining light with doxorubicin lowered cell viability and reduced several resistance-related genes, with 630 nm performing better. These are cell-culture findings, so their relevance to patients is uncertain and further research is needed.
- Who or what was studied
- MDA-MB-231 breast cancer cells in vitro that had acquired doxorubicin resistance
- Wavelengths
- 630, 980 nm
- Limits stated in the abstract
- The study used laboratory cell cultures, so the findings do not establish effects in humans and clinical potential remains unclear.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm, 980 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Low-level laser therapy, Light-emitting diode, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.